Revtemo for other cancers – pro
In the United States, selpercatinib is indicated for the treatment of::
adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.
people aged twelve years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.
people aged twelve years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
adults with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
Most RET mutations in BC appear after drug resistance, and CCDC6-RET and NCOA4-RET occur frequently. This patient has a RET mutaotn and she did ntor eswpond to initial chemotherapy, but she does not metastatic breast cancer.
Zhao L, Wang N, Zhang D, Jia Y, Kong F. A comprehensive overview of the relationship between RET gene and tumor occurrence. Front Oncol. 2023 Feb 14;13:1090757.
Lo Nigro C, Rusmini M, Ceccherini I. RET in breast cancer: pathogenic implications and mechanisms of drug resistance. Cancer Drug Resist. 2019 Dec 19;2(4):1136-1152.
Wu J, Subbiah V. RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond. Cancer Res. 2023 Oct 2;83(19):3159-3161